Gregory Renza

Jason Butler

Leszek Sulewski

Roanna Clarissa Ruiz

Serge Belanger

Anish Nikhanj

Brandon Folkes

John Janco

- CorMedix Inc. completed its acquisition of Melinta Therapeutics LLC on **August 29, 2025**, for an upfront consideration of **$300 million**, comprising **$260 million in cash** and **$40 million in CorMedix equity**.  **[1410098_0001213900-25-082956_ea0255371-8k_cormedix.htm:0]** **[1410098_0001213900-25-082956_ea025537101ex99-1_cormedix.htm:2]**  The agreement also includes potential regulatory milestone payments of up to **$25 million** and tiered royalties on REZZAYO™ and MINOCIN® U.S. net sales.  **[1410098_0001213900-25-082956_ea025537101ex99-1_cormedix.htm:2]** 
- The acquisition is expected to be **near-term accretive to EPS**, with **double-digit accretion anticipated in 2026**, and annual run-rate synergies projected between **$35 million and $45 million**.  **[1410098_0001213900-25-082956_ea025537101ex99-1_cormedix.htm:1]** 
- CorMedix has revised its pro forma 2025 combined revenue guidance to a range of **$325 million to $350 million**.  **[1410098_0001213900-25-082956_ea025537101ex99-1_cormedix.htm:1]**  Melinta's portfolio contributed **$120 million in total revenues in 2024** and is expected to generate **$125 million to $135 million for FY 2025**.  **[1410098_0001213900-25-082956_ea025537101ex99-1_cormedix.htm:1]** 
- The merger diversifies and strengthens CorMedix's product portfolio with **seven marketed products**, including REZZAYO™ and MINOCIN®, expanding its presence in the hospital acute care and infectious disease sectors.  **[1410098_0001213900-25-082956_ea025537101ex99-1_cormedix.htm:1]** **[1410098_0001213900-25-082956_ea025537101ex99-1_cormedix.htm:2]**  Key leadership appointments include **Susan Blum** as CFO, **Liz Hurlburt** as COO, and **Dr. Matt David** as Chief Business Officer.  **[1410098_0001213900-25-082956_ea025537101ex99-1_cormedix.htm:1]** **[1410098_0001213900-25-082956_ea025537101ex99-1_cormedix.htm:2]** **[1410098_0001213900-25-082956_ea0255371-8k_cormedix.htm:5]**

CorMedix (CRMD)